The company
IDEXX Laboratories, Inc.
IDXX · Nasdaq
IDXX stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 0.1% above that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−6 points in four weeks).
Statistics
- Rotation
- Above a falling average
- Weeks in an uptrend
- out for 38
- Industry in uptrend
- 52% +5 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $68.7M
- Officials’ trades on record
- 49
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.
Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
49 disclosed lines: House 35, Senate 5, executive 9; 11 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 23 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 17 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 16 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 12 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 11 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $50k–$100k | 27 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 17 Mar 2026filed 14 May 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 19 Feb 2026filed 14 May 2026 |
| Arjun Mody Executive branch: Office of Government EthicsSocial Security Administration | sold | $1k–$15k | 30 Jan 2026filed 10 Apr 2026 |
| April McClain Delaney House: U.S. House ClerkMD06 | solddependent child | $1k–$15k | 13 Jan 2026filed 2 Feb 2026 |
| April McClain Delaney House: U.S. House ClerkMD06 | solddependent child | $1k–$15k | 2 Dec 2025filed 5 Jan 2026 |
| April McClain Delaney House: U.S. House ClerkMD06 | solddependent child | $1k–$15k | 29 Oct 2025filed 4 Nov 2025 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Lawrence D. KingsleyDirector | sold | 2,203at $532.08 | 4 Sep 2026filed 9 Sep 2026 |
| Nimrata HuntExecutive Vice President | sold | 1,758at $634.57 | 3 Mar 2026filed 5 Mar 2026 |
| Nimrata HuntExecutive Vice President | sold | 2,693at $661.54 | 26 Feb 2026filed 27 Feb 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,281at $650.67 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,095at $651.49 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,669at $652.49 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,171at $653.68 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,111at $654.63 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,488at $655.85 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 1,343at $656.85 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 2,860at $657.84 | 26 Feb 2026filed 2 Mar 2026 |
| Jonathan Jay MazelskyPresident and CEO | sold | 3,660at $658.92 | 26 Feb 2026filed 2 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Everyone who traded it
Same industry
Government contracts
From its SEC filings
Analyst forecasts
No analyst forecasts yet.